• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 引发 ARDS 的机制:探索预防和治疗 SARS-CoV-2 的可能性。

Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2.

机构信息

College of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

出版信息

Front Cell Infect Microbiol. 2022 Jun 14;12:931061. doi: 10.3389/fcimb.2022.931061. eCollection 2022.

DOI:10.3389/fcimb.2022.931061
PMID:35774402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9237249/
Abstract

Novel coronavirus pneumonia (COVID-19) is spreading worldwide, causing great harm and stress to humans. Since patients with novel coronavirus (SARS-CoV-2) have a high probability of developing acute respiratory distress syndrome (ARDS) in severe cases, the pathways through which SARS-CoV-2 causes lung injury have become a major concern in the scientific field. In this paper, we investigate the relationship between SARS-CoV-2 and lung injury and explore the possible mechanisms of COVID-19 in ARDS from the perspectives of angiotensin-converting enzyme 2 protein, cytokine storm, activation of the immune response, triggering of Fas/FasL signaling pathway to promote apoptosis, JAK/STAT pathway, NF-κB pathway, type I interferon, vitamin D, and explore the possibility of prevention and treatment of COVID-19. To explore the possibility of SARS-CoV-2, and to provide new ideas to stop the development of ARDS in COVID-19 patients.

摘要

新型冠状病毒肺炎(COVID-19)在全球范围内传播,给人类带来了巨大的伤害和压力。由于新型冠状病毒(SARS-CoV-2)患者在严重情况下发生急性呼吸窘迫综合征(ARDS)的概率较高,因此 SARS-CoV-2 导致肺损伤的途径成为科学界关注的主要问题。本文从血管紧张素转换酶 2 蛋白、细胞因子风暴、免疫反应激活、Fas/FasL 信号通路触发促进细胞凋亡、JAK/STAT 通路、NF-κB 通路、I 型干扰素、维生素 D 等方面探讨 SARS-CoV-2 与肺损伤的关系,并探讨 COVID-19 中 ARDS 的可能机制,以期为 COVID-19 的防治提供新思路。探索 SARS-CoV-2 的可能性,并为阻止 COVID-19 患者 ARDS 的发展提供新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e58/9237249/b0cade7f7190/fcimb-12-931061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e58/9237249/6b1b286ff4ff/fcimb-12-931061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e58/9237249/b0cade7f7190/fcimb-12-931061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e58/9237249/6b1b286ff4ff/fcimb-12-931061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e58/9237249/b0cade7f7190/fcimb-12-931061-g002.jpg

相似文献

1
Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2.COVID-19 引发 ARDS 的机制:探索预防和治疗 SARS-CoV-2 的可能性。
Front Cell Infect Microbiol. 2022 Jun 14;12:931061. doi: 10.3389/fcimb.2022.931061. eCollection 2022.
2
Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?维生素 D 能否减轻 SARS-CoV-2 诱导的肺损伤?
Int J Infect Dis. 2021 Jan;102:196-202. doi: 10.1016/j.ijid.2020.10.059. Epub 2020 Oct 28.
3
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.血管紧张素转换酶 2(ACE2)在 COVID-19 所致急性呼吸窘迫综合征发病机制中的作用。
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
4
Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.Δ9-四氢大麻酚通过诱导免疫细胞凋亡,从而抑制细胞因子风暴,防止急性呼吸窘迫综合征导致的死亡。
Int J Mol Sci. 2020 Aug 28;21(17):6244. doi: 10.3390/ijms21176244.
5
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.JAK 抑制作为 COVID-19 患者的一种新治疗策略。
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
6
The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2.JAK-STAT 信号通路在 ACE2 辅助 COVID-19 感染中的潜在作用。
Gene. 2021 Feb 5;768:145325. doi: 10.1016/j.gene.2020.145325. Epub 2020 Nov 28.
7
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.新冠肺炎患者急性肺损伤/急性呼吸窘迫综合征应用促红细胞生成素作为辅助治疗的观点。
Arch Med Res. 2020 Oct;51(7):631-635. doi: 10.1016/j.arcmed.2020.08.002. Epub 2020 Aug 11.
8
The Many Faces of JAKs and STATs Within the COVID-19 Storm.JAKs 和 STATs 在 COVID-19 风暴中的多面性。
Front Immunol. 2021 Jul 13;12:690477. doi: 10.3389/fimmu.2021.690477. eCollection 2021.
9
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients.NF-κB 通路在重症 COVID-19 患者中的作用和治疗潜力。
Inflammopharmacology. 2021 Feb;29(1):91-100. doi: 10.1007/s10787-020-00773-9. Epub 2020 Nov 7.
10
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).Janus 激酶抑制剂芦可替尼治疗 SARS-CoV-2 诱导的急性呼吸窘迫综合征(ARDS)。
Leukemia. 2021 Oct;35(10):2917-2923. doi: 10.1038/s41375-021-01374-3. Epub 2021 Aug 12.

引用本文的文献

1
Novel Findings on the Development and Immunological Functions of Palatine Tonsils.腭扁桃体发育及免疫功能的新发现
Clin Rev Allergy Immunol. 2025 Jun 18;68(1):58. doi: 10.1007/s12016-025-09071-0.
2
Mucosal implications of oral Jak3-targeted drugs in COVID patients.口服靶向 Jak3 的药物对 COVID 患者的黏膜影响。
Mol Med. 2025 May 23;31(1):203. doi: 10.1186/s10020-025-01260-z.
3
Sex differences in adenosine deaminase activity associate with disparities in SARS-CoV-2 innate immunity.腺苷脱氨酶活性的性别差异与新冠病毒固有免疫的差异相关。

本文引用的文献

1
SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.SARS-CoV-2 的 Nsp13 编码一种 HLA-E 稳定肽,该肽能破坏表达 NKG2A 的 NK 细胞的抑制作用。
Cell Rep. 2022 Mar 8;38(10):110503. doi: 10.1016/j.celrep.2022.110503. Epub 2022 Feb 21.
2
T cell apoptosis characterizes severe Covid-19 disease.T 细胞凋亡是严重新冠肺炎疾病的特征。
Cell Death Differ. 2022 Aug;29(8):1486-1499. doi: 10.1038/s41418-022-00936-x. Epub 2022 Jan 22.
3
Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.
iScience. 2025 Apr 14;28(5):112418. doi: 10.1016/j.isci.2025.112418. eCollection 2025 May 16.
4
Targeting mTOR in myeloid cells prevents infection-associated inflammation.靶向髓系细胞中的mTOR可预防感染相关炎症。
iScience. 2025 Mar 4;28(4):112163. doi: 10.1016/j.isci.2025.112163. eCollection 2025 Apr 18.
5
Serum Lactate Dehydrogenase Levels Reflect the Lung Injury Extension in COVID-19 Patients at Hospital Admission.血清乳酸脱氢酶水平反映新冠病毒肺炎患者入院时肺损伤的程度。
Immun Inflamm Dis. 2025 Mar;13(3):e70168. doi: 10.1002/iid3.70168.
6
Study protocol for COVID-19 breakthrough infections and vaccine-induced immune response among a cohort of healthcare workers, Bangladesh.孟加拉国一组医护人员中新冠病毒突破性感染及疫苗诱导免疫反应的研究方案
PLoS One. 2024 Dec 31;19(12):e0316121. doi: 10.1371/journal.pone.0316121. eCollection 2024.
7
Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced ‎oxidative stress and inflammation in mice‎: ‎An study.利福昔明联合甲泼尼龙对脂多糖诱导的小鼠氧化应激和炎症的新治疗作用:一项研究。
Toxicol Rep. 2024 Nov 12;13:101808. doi: 10.1016/j.toxrep.2024.101808. eCollection 2024 Dec.
8
Potential therapeutic and ameliorative effects of ramipril alone and in combination with methylprednisolone for the cytokine releasing syndrome in mice: An in vivo study.雷米普利单独及与甲泼尼龙联合应用对小鼠细胞因子释放综合征的潜在治疗和改善作用:一项体内研究。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5845-5865. doi: 10.1007/s00210-024-03659-7. Epub 2024 Nov 30.
9
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.CD95L选择性抑制剂阿苏单抗在中重度新冠肺炎住院患者中的疗效和安全性:ASUNCTIS,一项多中心、随机、开放标签、对照的2期试验
EClinicalMedicine. 2024 Oct 24;77:102879. doi: 10.1016/j.eclinm.2024.102879. eCollection 2024 Nov.
10
An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.儿童在 COVID-19 大流行期间的肺部并发症概述:未来的教训。
Immun Inflamm Dis. 2024 Nov;12(11):e70049. doi: 10.1002/iid3.70049.
ARDS、肺纤维化和 COVID-19 之间的共同点:ATX 作为治疗靶点的潜力。
Front Immunol. 2021 Oct 4;12:687397. doi: 10.3389/fimmu.2021.687397. eCollection 2021.
4
The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication.NF-κB 转录足迹对于 SARS-CoV-2 复制至关重要。
J Virol. 2021 Nov 9;95(23):e0125721. doi: 10.1128/JVI.01257-21. Epub 2021 Sep 15.
5
The role of vitamin D in the age of COVID-19: A systematic review and meta-analysis.维生素 D 在 COVID-19 时代的作用:系统评价和荟萃分析。
Int J Clin Pract. 2021 Nov;75(11):e14675. doi: 10.1111/ijcp.14675. Epub 2021 Aug 6.
6
Triptolide dose-dependently improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS mice.雷公藤甲素通过抑制 NF-κB 活化改善脂多糖诱导的急性呼吸窘迫综合征肺泡高凝及纤溶抑制。
Biomed Pharmacother. 2021 Jul;139:111569. doi: 10.1016/j.biopha.2021.111569. Epub 2021 May 24.
7
Acute respiratory distress syndrome.急性呼吸窘迫综合征。
Lancet. 2021 Aug 14;398(10300):622-637. doi: 10.1016/S0140-6736(21)00439-6. Epub 2021 Jul 1.
8
Role of SARS-CoV-2 and ACE2 variations in COVID-19.SARS-CoV-2 和 ACE2 变异在 COVID-19 中的作用。
Biomed J. 2021 Jun;44(3):235-244. doi: 10.1016/j.bj.2021.04.006. Epub 2021 Apr 21.
9
Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2.SARS-CoV-2 的 ORF7a 蛋白介导的 NF-κB 激活和促炎细胞因子表达的诱导。
Sci Rep. 2021 Jun 29;11(1):13464. doi: 10.1038/s41598-021-92941-2.
10
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.体液免疫对 SARS-CoV-2 的作用及对 COVID-19 发病机制的影响。
Mol Cells. 2021 Jun 30;44(6):392-400. doi: 10.14348/molcells.2021.0075.